Coloplast A/S (CLPBY) Stock Forecast & Price Target

$12.60 -0.15 (-1.18%)

(As of 11/20/2024 ET)

Coloplast A/S - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Hold

Based on 1 Analyst Ratings

Sell
0

Hold
1

Buy
0

Based on 1 Wall Street analysts who have issued ratings for Coloplast A/S in the last 12 months, the stock has a consensus rating of "Hold." Out of the 1 analysts, 1 has given a hold rating for CLPBY.

Consensus Price Target

N/A

Get the Latest News and Ratings for CLPBY and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Coloplast A/S and its competitors.

CLPBY Analyst Ratings Over Time

Type	Current Forecast 11/22/23 to 11/21/24	1 Month Ago 10/23/23 to 10/22/24	3 Months Ago 8/24/23 to 8/23/24	1 Year Ago 11/22/22 to 11/22/23
Strong Buy	0 Strong Buy rating(s)	N/A	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	0 Buy rating(s)	N/A	0 Buy rating(s)	1 Buy rating(s)
Hold	1 Hold rating(s)	N/A	2 Hold rating(s)	5 Hold rating(s)
Sell	0 Sell rating(s)	N/A	0 Sell rating(s)	1 Sell rating(s)
Consensus Price Target	N/A	N/A	N/A	N/A
Forecasted Upside	N/A	N/A	N/A	N/A
Consensus Rating	Hold	N/A	Hold	Hold

JD Vance Predicts: Wall Street vs. Trump & Your Money (Ad)

Trump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purposely crash the bond market to sabotage Trump's comeback.

Get your free guide NOW before it's too late.

CLPBY Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

CLPBY Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Coloplast A/S Stock vs. The Competition

Type	Coloplast A/S	Medical Companies	S&P 500
Consensus Rating Score	0.00	2.80	2.50
Consensus Rating	N/A	Moderate Buy	Moderate Buy
Predicted Upside	N/A	26,931.54% Upside	9.83% Upside
News Sentiment Rating	Neutral News See Recent CLPBY News	Neutral News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating
11/18/2024	Hsbc Global Res 0 of 5 stars	S. Gupta Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Moderate Sell ➝ Hold
9/7/2023	Royal Bank of Canada 4 of 5 stars		Initiated Coverage	Sector Perform
9/5/2023	The Goldman Sachs Group 2 of 5 stars		Initiated Coverage	Neutral
7/10/2023	DNB Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Hold ➝ Buy
6/1/2023	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Overweight ➝ Equal Weight
5/12/2023	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Neutral ➝ Underweight
3/29/2023	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Underweight ➝ Equal Weight
3/7/2023	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Market Perform

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 02:56 PM ET.

Should I Buy Coloplast A/S Stock? CLPBY Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Wednesday, November 6, 2024. Please send any questions or comments about these Coloplast A/S pros and cons to contact@marketbeat.com.

Coloplast A/S
Bull Case

Here are some ways that investors could benefit from investing in Coloplast A/S:

Coloplast A/S stock price recently crossed below its 50-day moving average, potentially indicating a buying opportunity as the stock may be undervalued.
Coloplast A/S has a strong net margin of 18.89%, indicating efficient cost management and profitability.
Coloplast A/S reported a return on equity of 31.39%, showcasing the company's ability to generate profit from shareholders' equity.
Coloplast A/S has a market capitalization of $28.64 billion, reflecting the company's size and stability in the market.
Coloplast A/S has a diverse product portfolio in intimate healthcare products and services, providing a stable revenue stream across multiple markets.

Coloplast A/S
Bear Case

Investors should be bearish about investing in Coloplast A/S for these reasons:

Coloplast A/S has a relatively high price-to-earnings ratio of 40.18, which may indicate that the stock is currently overvalued.
Coloplast A/S has a price-to-earnings-growth ratio of 3.45, suggesting that the stock may be expensive relative to its earnings growth potential.
Coloplast A/S has a beta of -0.01, indicating that the stock's price is not very sensitive to market movements, potentially leading to lower returns in volatile market conditions.
Coloplast A/S has a current ratio of 0.85 and a quick ratio of 0.56, which may raise concerns about the company's short-term liquidity and ability to meet immediate financial obligations.
Coloplast A/S operates in a competitive market for healthcare products and services, which could pose challenges in maintaining market share and profitability over the long term.

CLPBY Forecast - Frequently Asked Questions

: 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Coloplast A/S in the last year. There is currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" CLPBY shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CLPBY, but not buy additional shares or sell existing shares.
: According to analysts, Coloplast A/S's stock has a predicted downside of -100.00% based on their 12-month stock forecasts.
: Over the previous 90 days, Coloplast A/S's stock had 1 upgrade by analysts.
: Coloplast A/S has been rated by research analysts at Hsbc Global Res in the past 90 days.
: Analysts like Coloplast A/S less than other "medical" companies. The consensus rating for Coloplast A/S is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how CLPBY compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

2024 Election Year Stocks: Uncover Hidden Gems! (Ad)

In the lead-up to the pivotal 2024 election year, we're excited to present our comprehensive report, "Election Year Investment Gems: Stock Poised To Takeoff In 2024," brimming with insights and opportunities you won't want to miss.

Secure your copy now by clicking this link.

This page (OTCMKTS:CLPBY) was last updated on 11/21/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Coloplast A/S (CLPBY) Stock Forecast & Price Target